ImmuPharma PLC

ImmuPharma cancer programme talks continue

Conversations with Incanthera are continuing even though an extended period of exclusivity has lapsed

cancer cells
The company is keen to find a partner for its Nucant cancer programme

ImmuPharma PLC (LON:IMM) said a period of exclusivity has run out between it and Incanthera Limited, which allows the ImmuPharma to discuss collaborations with other potential partners for its Nucant cancer programme.

“Notwithstanding the expiry of the exclusivity period, discussions with Incanthera are continuing in good faith for broader collaboration,” the AIM-listed life sciences group told investors.

READ: ImmuPharma says article shines light on potential of peptide subsidiary

“There can be no guarantee that any agreement will be reached with Incanthera on a broader collaboration.”

An outline deal was inked last September, at which point ImmuPharma took a £2mln stake in Incanthera. The deadline for a definitive agreement was extended from the end of December to the end of March.

Quick facts: ImmuPharma PLC

Price: £0.09

Market: AIM
Market Cap: £15.73 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...



Immupharma chairman details £2.66mln financing and open label extension study

ImmuPharma PLC’s (LON:IMM) chairman Tim McCarthy caught up with Proactive London's Andrew Scott to discuss the results of a follow-up study which was designed to evaluate Lupuzor’s safety and tolerability. McCarthy says the six month extension study confirmed its outstanding and robust...

on 4/7/19

2 min read